GO
Loading...

Myriad Genetics Inc

More

  • Is Health Care Immune To 2011 Ills? Thursday, 30 Dec 2010 | 5:53 PM ET

    Amid so much uncertainty about the prospects for next year's economy, could health care be one sector that’s immune to a potential double-dip?

  • Following are some moves you may have missed. Find out why Semiconductor Manufacturing popped while Myriad Genetics and Sanderson Farms dropped.

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • Four Sectors Most Likely To Lead The Market Wednesday, 28 Oct 2009 | 2:57 PM ET
    Recovery sign

    As the US economic recovery looms larger, the gray cloud that has hung over the stock market for so long is finally starting to fade. Here's four sectors likely to outperform in the months and year ahead.

  • Opportunities in Small Caps: Stock Picker Monday, 19 Oct 2009 | 11:25 AM ET

    Stocks moved higher on Monday, despite a wobbly start. Where should investors look to put their money? Sam Dedio, portfolio manager of the Artio Small Cap Fund, which is up almost 70 percent this year, shared his small cap stock picks.

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • Pops & Drops: General Mills, PetroChina Wednesday, 1 Jul 2009 | 6:18 PM ET

    Following are the day’s biggest winners and losers. Find out why shares of General Mills and Petrochina popped while Marriott and Myriad Genetics dropped.

  • Upcoming Rebalancing of the Russell Indices Tuesday, 16 Jun 2009 | 8:55 AM ET

    The Dow Industrials briefly turned positive for the year earlier this morning. WAHOO! But wait…the S&P 500 turned positive for 2009 nearly one month ago and is now up over 4.5% this year. So why the performance lag in the Dow (compared to the S&P)?

  • Cramer makes the call on viewers' favorite stocks.

  • Lightning Round: Wyeth, Oracle, UPS and More Wednesday, 1 Apr 2009 | 8:58 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • 5 Stocks with Strengthening Financials Wednesday, 25 Mar 2009 | 9:17 AM ET

    When AIG's CEO, Edward Liddy, testified before Congress last week, we took a look back at the company's historical quarterly financials to identify when the proverbial "writing on the wall" could have been first seen.  Here is a screen looking for companies that have had increasingly stronger and stronger 10-Q reporting.

  • '09 Sector To Watch: Biotech Monday, 5 Jan 2009 | 6:06 PM ET

    Will M&A activity boost biotech stocks in 2009?

  • A Crestor Day Monday, 10 Nov 2008 | 6:18 PM ET

    One of the weapons widely used to fight cholesterol might be more powerful than previously believed. Is there a trade here?

  • The Latest Picks That Paid – Friday July 11th Friday, 11 Jul 2008 | 6:48 PM ET
    Quicker Ticker

    Our traders are good - but you knew that! Check out their latest picks that paid.

  • Pops & Drops: Chesapeake Energy, Circuit City... Wednesday, 2 Jul 2008 | 6:28 PM ET

    Following are the day’s biggest winners and losers. Find out why shares of Chesapeake Energy and AstraZeneca popped while Circuit City and Western Union dropped.

  • Biotech A Bear Fighter? Tuesday, 1 Jul 2008 | 6:31 PM ET

    What are the best plays when the market enters bear territory?

  • Abbott, Boston Scientific Stents & Stuff Tuesday, 1 Jul 2008 | 10:33 AM ET
    Heart Stent

    So, I can now safely say, with complete confidence, that Food and Drug Administration approval of the new Abbott drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4.

  • Market Midterm: Healthcare Wednesday, 25 Jun 2008 | 6:30 PM ET

    Here's how you can play healthcare with either a McCain or Obama presidency!

  • Dow Falls Below 12,000 Friday, 20 Jun 2008 | 5:53 PM ET

    The Dow closed sharply lower Friday, registering its third triple-digit loss in four sessions. What's the "Word on the Street?"

  • Options Eye Alzheimer's, GM, AmeriCredit Thursday, 19 Jun 2008 | 8:26 AM ET

    Options are eyeing the drug sector's Alzheimer's treatments, according to one observer.